Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | P4HB | P07237 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581345 | 1.00 | GRM4 (0.36) | GRM4HDAC1P4HBSYKADRA1D | |
| SCHEMBL17064311 | 1.00 | GRM4 (0.36) | GRM4HDAC1P4HBSYKADRA1D | |
| SCHEMBL23429188 | 1.00 | GRM4 (0.36) | GRM4HDAC1P4HBSYKADRA1D | |
| SCHEMBL18623225 | 1.00 | GRM4 (0.36) | GRM4HDAC1P4HBSYKADRA1D | |
| SCHEMBL25667322 | 0.87 | ADRA1D (0.39) | HDAC1P4HBSYKADRA1DADRA1A | |
| SCHEMBL25667323 | 0.87 | ADRA1D (0.39) | HDAC1P4HBSYKADRA1DADRA1A | |
| SCHEMBL17064633 | 0.87 | GRIN2D (0.38) | GRM4HDAC1P4HBSYKADRA1D | |
| SCHEMBL30834043 | 0.87 | GRIN2D (0.38) | GRM4HDAC1P4HBSYKADRA1D | |
| SCHEMBL1528612 | 0.80 | CNR1 (0.44) | ADRA1DADRA1AADRA2BADRA1BCNR1 | |
| SCHEMBL1528610 | 0.80 | CNR1 (0.44) | ADRA1DADRA1AADRA2BADRA1BCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114591212-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-4019022-B1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2024-01-31 | — | — | EP | disclosed |
| US-11807605-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4019022-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114591212-A | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-108289893-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220098151-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807605-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | GRM4 4830/4885HDAC1 1075/4885P4HB 860/4885 |
| US-20220098151-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | GRM4 4830/4885HDAC1 1075/4885P4HB 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.